Drug response studies refer to investigations that evaluate how individual patients or specific cell lines respond to different drugs or treatments. These studies aim to understand and predict the effectiveness and potential side effects of various drugs in treating specific diseases or conditions. In drug response studies, samples or cells are exposed to different drugs or drug combinations, and their responses are assessed through various methods such as cell viability assays, gene expression analysis, protein activity measurements, or imaging techniques. They provide insights into the sensitivity or resistance of a patient’s cells or a specific cell line to particular drugs, allowing for personalized treatment selection or identification of potential therapeutic targets. Drug response studies play a critical role in guiding clinical decision-making, optimizing treatment outcomes, and advancing our understanding of drug efficacy and resistance.
Drug Libraries and Compounds
Streamline Your Screening Process With Over 3,000 Unique Small Molecules
Comprehensive libraries of drugs and compounds, including FDA-approved drugs, investigational compounds, or natural products, for screening and assessing their effects on cellular responses.
Enzo has a long and successful track record in identifying, synthesizing, and commercializing valuable known bioactives for use as research tools. Our small molecules are available as either stand-alone products or curated libraries, offering ultimate flexibility and value. Our long-standing, flagship SCREEN-WELL® Compound Library product family offers an easy, ready-to-use method for compound screening
Drug resistance is a phenomenon mediated by up-regulation of a family of transmembrane ATP Binding Cassette (ABC) transporter proteins. Overexpression of ABC transporter proteins accelerates removal of toxic agents from the cell, for example the efflux of chemotherapeutic agents from tumor cells, or of antibiotics from resistant strains of bacteria.
Distinguishing between apoptosis and necrosis provides valuable insights into the specific pathways through which a drug induces cell death, aiding researchers in assessing the safety and efficacy of potential drug candidates.
Readily distinguishes between healthy, early apoptotic, late apoptotic and necrotic cells
Optimized for both fluorescence microscopy and flow cytometry applications
Specifically designed for use with GFP-expressing cell lines and cells expressing blue or cyan fluorescent proteins (BFPs, CFPs)
Distinguish Between Healthy, Early Apoptotic, Late Apoptotic, and Necrotic Cells
GFP-CERTIFIED ® Apoptosis/Necrosis Detection Kit detects four distinct cell states. Mitochondrial GFP-expressing HeLa cells were treated with 2μM Staurosporine for 4 hours. The apoptosis detection reagent (gold) and necrosis detection reagent (red) specifically detect cell states with clear spectral separation from mitochondria-associated GFP signal. Healthy cells (A), cells undergoing apoptosis (B), cells undergoing late-stage apoptosis (C), and necrotic cells (D).
C-Reactive Protein (CRP) is a pentraxin family protein that is widely used as a biomarker for systemic inflammation and tissue injury. Its primary role in innate immunity is to function as an opsonin for pathogens via activation of the complement pathway and through binding to Fc gamma receptors. CRP has been shown to play an important role in a variety of pathological pathways.
Sensitive assay detects as little as 12.685 ng/ml in serum and plasma
Highly specific with negligible reactivity to other family members